Gastroesophageal reflux disease: Diagnosis and management

American Family Physician

Volumn 59, Issue 5, 1999, Pages 1161-1169

  Scott, Mark ^a   Gelhot, Aimee R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANTACID AGENT; CIMETIDINE; CISAPRIDE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE;

ADVERSE DRUG REACTION; AMBULATORY MONITORING; ANTIREFLUX OPERATION; ARTICLE; CLINICAL TRIAL; ESOPHAGOSCOPY; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; PATHOPHYSIOLOGY; RECURRENT DISEASE; STOMACH FUNDOPLICATION;

CHRONIC DISEASE; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DRUG INTERACTIONS; ESOPHAGITIS, PEPTIC; GASTROESOPHAGEAL REFLUX; HUMANS; LIFE STYLE; PATIENT EDUCATION; PREVALENCE; RECURRENCE; SEVERITY OF ILLNESS INDEX; TEACHING MATERIALS; UNITED STATES;

EID: 0033106207     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Orlando RC. The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol 1997;92(4 suppl):3S-5S.
2. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92:37-41.
3. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux dissease and its complications with Barrett's esophagus. Am J Gastroenterol 1997;92:27-31.
4. Fennerty MB. Medical treatment of gastroesophageal reflux disease in the managed care environment. Semin Gastrointest Dis 1997;8:90-9.
5. Fennerty MB, Castell D, Fendrick AM, Halpern M, Johnson D, Kahrilas PJ, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: suggested disease management guidelines. Arch Intern Med 1996; 156:477-84.
6. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996;276:983-8.
7. Kauer WK, Peters JH, DeMeester TR, Feussner H, Ireland AP, Stein HJ, et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 1997;122:874-81.
8. Quigley EM. Gastroesophageal reflux disease: the roles of motility in pathophysiology and therapy [Editorial]. Am J Gastroenterol 1993;88:1649-51.
9. Katz PO. Pathogenesis and management of gastroesophageal reflux disease. J Clin Gastroenterol 1991;13(suppl):S6-15.
10. Tefera L, Fein M, Ritter MP, Bremner CG, Crookes PF, Peters JH, et al. Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease. Am Surg 1997;63:933-6.
11. Richter JE. Typical and atypical presentations of gastroesophageal reflux disease: the role of esophageal testing in diagnosis and management. Gastroenterol Clin North Am 1996;25:75-102.
12. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman HA, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997;92:1997-2000.
13. Chen MY, Ott DJ, Sinclair JW, Wu WC, Gelfand DW. Gastroesophageal reflux disease: correlation of esophageal pH testing and radiographie findings. Radiology 1992;185:483-6.
14. Castell DO, Johnston BT. Gastroesophageal reflux disease: current strategies for patient management. Arch Fam Med 1996;5:221-7.
15. Richter JE. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol 1997;92(4 suppl):30S-34S.
16. DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med 1995;155:2165-73.
17. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991:151:448-54.
18. Welage LS, Berardi RR. Drug interactions with antiulcer agents: considerations in the treatment of acid-peptic disease. J Pharm Pract 1994;7:177-95.
19. Howden CW. Optimizing the pharmacology of acid control in acid-related disorders. Am J Gastroenterol 1997;92(4 suppl):17S-19S.
20. Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992;33:118-24.
21. Rush DR, Stelmach WJ, Young TL, Kirchdoerfer LJ, Scott-Lennox J, Holverson HE, et al. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 1995;41:126-36.
22. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
23. Propulsid. Package insert. Titusville, N.J.: Janssen Pharmaceutica Inc., 1998.
24. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161-7.
25. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:859-67.
26. Skoutakis VA, Joe RH, Hara DS. Comparative role of omeprazole in the treatment of gastroesophageal reflux disease. Ann Pharmacother 1995;29:1252-62.
27. Monette J, Mogun H, Bohn RL, Avorn J. Concurrent use of antiulcerative agents. J Clin Gastroenterol 1997;24:207-13.
28. Hinder RA, Perdikis G, Klinger PJ, DeVault KR. The surgical option for gastroesophageal reflux disease. Am J Med 1997;103:144S-148S.